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The balance between oxidative and nonoxidative
glucosemetabolism is essential for a number of path-
ophysiological processes. By deleting enzymes that
affect aerobic glycolysis with different potencies,
we examine how modulating glucose metabolism
specifically affects hematopoietic and leukemic cell
populations. We find that a deficiency in theM2 pyru-
vate kinase isoform (PKM2) reduces the levels of
metabolic intermediates important for biosynthesis
and impairs progenitor function without perturbing
hematopoietic stemcells (HSCs),whereas lactatede-
hydrogenase A (LDHA) deletion significantly inhibits
the function of both HSCs and progenitors during
hematopoiesis. In contrast, leukemia initiation by
transforming alleles putatively affecting either HSCs
or progenitors is inhibited in the absence of either
PKM2 or LDHA, indicating that the cell-state-specific
responses tometabolic manipulation in hematopoie-
sisdonot apply to the settingof leukemia. This finding
suggests that fine-tuning the level of glycolysis
may be explored therapeutically for treating leukemia
while preserving HSC function.
INTRODUCTION
Metabolic state influences cell state, and metabolism must be
adapted to support specific cell functions. Warburg’s finding
that cancer cells preferentially rely on aerobic glycolysis (AG)
is a well studied example of how glucose metabolism reflects
a particular cell state (Cairns et al., 2011). Nonetheless,
the requirement for specific metabolic programs in defined
populations of parenchymal cells remains to be explored.
Furthermore, little is known about what differential metabolic re-Cquirements, if any, exist between normal proliferative cell popu-
lations and their malignant counterparts. This is an issue that the
hematopoietic system is uniquely well suited to address. Studies
on cancer cell lines have indicated that increased glucose up-
take with lactate production, regardless of oxygen concentra-
tion, or AG is promoted, in part, by expression of the M2 isoform
of pyruvate kinase (PK) (Christofk et al., 2008a) and the muscle
form of lactate dehydrogenase A (LDHA) (Fantin et al., 2006; Le
et al., 2010). These two enzymes catalyze the final two steps in
glucose fermentation to lactate, and both have attracted atten-
tion as potential therapeutic targets. PK catalyzes the conversion
of phosphoenolpyruvate (PEP) and ADP to pyruvate and ATP. In
mammals, the M1 and M2 isoforms are different splice products
of PK expressed in tissues other than liver, kidney, and red blood
cells. PKM1 is expressed in differentiated adult tissues that have
a high demand for ATP production and metabolize glucose
preferentially via oxidative phosphorylation. PKM2 is expressed
in early embryonic tissues, cancers, and adult cells that have
high anabolic activity (Clower et al., 2010; Imamura and Tanaka,
1972). Although PKM1 and PKM2 only differ in the alternatively
spliced exon, there aremarked differences in their enzymatic ac-
tivity and regulation. PKM1 exists as a stable tetramer and is
constitutively active. The activity of PKM2, in contrast, is regu-
lated allosterically and can exist as a high-activity tetramer
or a low-activity nontetramer (Anastasiou et al., 2012). PKM2
is activated by metabolic intermediates such as fructose-
1,6-bisphosphate, serine, and succinyl-5-aminoimidazole-4-
carboxamide-1-ribose-50-phosphate and inhibited by tyrosine-
phosphorylated peptides, reactive oxygen species (ROS), and
posttranslational modifications (Chaneton et al., 2012; Christofk
et al., 2008b; Hitosugi et al., 2009; Keller et al., 2012; Lv et al.,
2011; Yalcin et al., 2010). Reduced PKM2 activity favors AG
and the generation of intermediates necessary for macromole-
cule synthesis. Pharmacological activation of PKM2 or forced
expression of PKM1 decreases AG in cancer cell lines and sup-
presses tumorigenesis (Anastasiou et al., 2012; Israelsen et al.,
2013; Parnell et al., 2013). PKM2 may, therefore, serve as aell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc. 1309
Figure 1. Conditional Deletion of PKM2 in
Mouse BM
(A) PKM2 is the predominant PK isoform ex-
pressed by BM hematopoietic cells. RNA was
prepared from muscle (M), spleen (Spl), whole BM
(WBM), BM subsets (LKS, SLAM, and GMP), and
leukemic cell lines (K562 and THP1). The PKM
transcript was amplified by RT-PCR, followed by
digestion with PstI for exon 10 (PKM2) and/or NcoI
for exon 9 (PKM1). Un, uncut WBM.
(B) qPCR assay of PKM2 expression in BM sub-
sets. LK, LincKit+Sca1.
(C) Pkm2fl/fl:Mx1-cre+ (M2/) or Pkm2fl/fl:Mx1-
cre (M2fl/fl) mice were injected with poly(I:C) to
delete exon 10 of PKM2. Genomic DNA isolated
from BM MNCs was analyzed by PCR (top). cDNA
was amplified and digested by restriction enzymes
as described in (A) (bottom). The arrow indicates
the misspliced PKM transcript.
(D) qPCR of PKM2 and PKM1 transcripts from
Pkm2fl/fl and Pkm2/ BM cells.
(E) Western blotting of PKM proteins in BM MNCs.
(F) Flow cytometry analysis of PKM2 (left) and
PKM1 (right) expressing cells in the BM (n = 4-5).
Representative FACS plots are shown in Figure S1.tunable means by which the balance of oxidative phosphoryla-
tion versus AG can be shifted to meet different cellular needs.
A distinct, defined regulator of AG versus oxidative phosphor-
ylation is the tetrameric enzyme lactate dehydrogenase (LDH),
which catalyzes the conversion of pyruvate to lactate. By
oxidizing nicotinamide adenine dinucleotide, reduced (NADH),
this reaction regenerates nicotinamide adenine dinucleotide
(NAD+) to support continued flux through glycolysis. Two LDH
subunit isoforms, lactate dehydrogenase A (LDHA) and lactate
dehydrogenase B (LDHB), are encoded by different genes and
combine in varying ratios to form five LDH isozymes (A4,
A3B1, A2B2, A1B3, and B4), each with distinct kinetic proper-
ties. Many human cancers have higher LDHA levels than normal
tissues, and elevated LDHA expression has been correlated with
poor prognosis and drug resistance (Behringer et al., 2003; Di-
mopoulos et al., 1991). In addition, LDHA is a direct target
gene of c-Myc and HIF-1a and thought to be a means by which
they reprogram metabolism in cancer (Semenza et al., 1996;
Shim et al., 1997). Consistent with these observations, inhibition
of LDHA by either RNAi or small molecules suppresses AG, af-
fects the cellular redox state, and blocks tumor progression
(Fantin et al., 2006; Granchi et al., 2011; Le et al., 2010).
In the hematopoietic system, hematopoietic stem cell (HSC)
function has been shown to be sensitive to metabolic perturba-
tions including depletion of HIF-1a and pyruvate dehydrogenase
kinase (PDK) (Simsek et al., 2010; Takubo et al., 2010, 2013). It is
not clear whether distinctive cell states, such as progenitors
or hematopoietic malignancies, have similar metabolic depen-1310 Cell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc.dencies as HSCs. Given the role of
PKM2 and LDHA in mediating AG in can-
cer, genetic manipulation of PKM2 and
LDHA in the hematopoietic system pro-
vides a unique opportunity to addressthe importance of AG in the context of defined normal andmalig-
nant cell types in vivo. In this study, we observed that PKM2 and
LDHA are the predominant isoforms expressed by bone marrow
(BM) hematopoietic cells and, therefore, used engineeredmouse
strains to conditionally alter those genes in normal andmalignant
hematopoietic cells. We demonstrated that modulating AG has
effects on normal hematopoietic cells that depend upon the
cell state and negatively impact leukemic growth regardless of
cell state. The differential sensitivity of normal and malignant
cells to modulation of AG suggests a potential therapeutic
opportunity for leukemia intervention.
RESULTS
PKM2 Is the Predominant Isoform of PK Expressed in
Normal Hematopoietic and Leukemic Cells
To determine which PKM isoform is expressed in BM hemato-
poietic cells in mice, we isolated HSPCs (Lin-cKit+Sca1+,
LKS), long-term HSCs (Lin-cKit+Sca1+CD150+CD48-, SLAM),
and granulocyte/macrophage progenitors (Lin-Sca1-cKit+
CD34+CD16/32hi, GMP); performed RT-PCR across the alterna-
tively spliced exons; and distinguished between the Pkm1 and
Pkm2 messages by restriction enzyme digestion (Clower et al.,
2010; Israelsen et al., 2013). Our data show that PKM2 is the pre-
dominant PK isoform mRNA species present in all BM hemato-
poietic cells (Figure 1A). Expression of PKM2 was confirmed
by isoform-specific quantitative PCR (qPCR) and western blot-
ting (Figures 1B and 1E). The expression of PKM2 was also
examined by intracellular staining with PKM2 antibody and flow
cytometry (Figure S1A, available online). PKM2 protein levels ap-
peared to be the highest in Lin+ cells. In Lin cells, all subsets
expressed similar levels of PKM2, except the LincKitSca1+
(LS) cells that expressed lower levels. There was no difference
in PKM2 expression between LKS/CD150+ cells and LKS/
CD150 cells. PKM2 was also expressed in leukemic cell lines
(Figure 1A).
Conditional Deletion of PKM2 in the Hematopoietic
Lineage
Because PKM2 is implicated in promoting AG in cancer cells, we
tested whether it is also important for the maintenance of
glycolysis in HSCs (Suda et al., 2011). To this end, we utilized a
conditional knockout (KO) mouse strain that contains a floxed
PKM2-specific exon 10 (Pkm2fl/fl) (Israelsen et al., 2013) and an
Mx1-cre transgene (Pkm2fl/flMx1-cre+). Pkm2fl/fl:Mx1-cre
micewere used aswild-type (WT) controls. In thismodel, expres-
sion of cre recombinase in BM hematopoietic cells is induced by
intraperitoneal (i.p.) administration of polyinosinic:polycytidylic
acid (poly(I:C)). Following poly(I:C) injection, BM cells were
analyzed, and deletion of PKM2 was confirmed by genomic
DNA, mRNA, and protein evaluation (Figures 1C–1E). Interest-
ingly, deletion of PKM2 led toPKM1expression in all BMsubpop-
ulations (Figures 1C–1E). To quantify the efficiency of PKM2
deletion and PKM1 expression, we performed an intracellular
staining of PKM1 andPKM2 proteins followed by flow cytometry.
Nearly 90% of whole BM cells were depleted with PKM2 and ex-
pressed PKM1 poly(I:C) injection (Figure 1F; Figures S1B and
S1C). In the progenitor and stem cell populations, deletion of
PKM2 and expression of PKM1 were induced in 100% of cells
(Figure 1F; FiguresS1BandS1C). Interestingly, stainingcellswith
an antibody recognizing a common epitope shared by PKM1 and
PKM2 (anti-PKM),weobserved lower PKexpression inPKM2KO
cells compared with a control (Figure S1D). Therefore, although
PKM1 is induced in PKM2 mutant cells, it is expressed at lower
levels than PKM2 in WT cells. This finding is further supported
by lower PK enzymatic activity in Pkm2/ cells than in WT cells
(Figure S1E). Deletion of exon 10 led to the appearance of a
misspliced PKM transcript (Figure 1C). A similar transcript was
observed following exon 10 deletion in tumors and represented
direct joining of exon 8 to exon 11 that was not translated into a
functional protein (Israelsen et al., 2013). Taken together, these
results suggest that incomplete repression of exon 9 during
splicing allows some PKM1 expression in hematopoietic cells
following excision of exon 10 but that overall PK expression is
less than that in WT cells. Because PKM1 favors glucose meta-
bolism via oxidative phosphorylation, whereas PKM2 promotes
AG, expression of PKM1 in Pkm2/ cells provides an ideal sys-
tem to address which metabolic mode plays a more important
role in hematopoietic cells.
Deletion of PKM2 Does Not Affect Hematopoiesis under
Homeostatic Conditions but Compromises Long-Term
Hematopoiesis in Transplantation
To examine the effect of PKM2 deletion on normal hematopoie-
sis, spleen and BMwere analyzed 1 month following poly(I:C) in-
jection. No significant difference in spleen size, BM cellularity, orCcolony-forming ability was observed between Pkm2/ and
Pkm2fl/fl mice (data not shown). Blood counts of mice for 1
year after deletion did not reveal significant differences between
WT and KO mice (data not shown). Deletion of PKM2 was main-
tained throughout the duration of the experiment (Figure S1F).
Therefore, PKM2 is not required for normal hematopoiesis under
homeostasis. Testing whether PKM2 plays a role in hematopoi-
esis under stress conditions, we performed competitive BM
transplantation to assess the BM repopulating ability. Pkm2/
or control (CD45.1+) BM mononuclear cells (MNCs) were mixed
with competitor BM MNCs (CD45.2+) at a 1:1 ratio and trans-
planted into lethally irradiated congenic mice (CD45.2+). Periph-
eral blood was analyzed monthly to measure the contribution
from different genotypes. After 6 months, the PKM2/ BM cells
displayed a moderate but significant decrease in repopulating
mature blood cells compared with the WT control (Figure 2A).
Interestingly, the defect was observed specifically in the
lymphoid lineage. We then analyzed the BM chimerism at this
time point. There was no significant difference in the levels of
HSC (SLAM) chimerism. However, progenitor populations,
including the LS subset, displayed less chimerism in the
Pkm2/ group (Figure 2B).
Because the competitive disadvantage of PKM2/ cells in the
BM was observed in progenitor populations, we hypothesized
that PKM2might play a role in hematopoietic progenitor cell pro-
liferation and expansion. HSPCs sorted from primary recipients
were transplanted in equal numbers with competitor BM MNCs
into secondary recipient mice. Pkm2/ HSPCs displayed a
marked defect in repopulating both myeloid and lymphoid prog-
eny as early as 4–8weeks following transplantation (Figure 2C). A
similar phenotype was observed in tertiary transplantation with
HSPCs (Figure 2D). Because the Mx1 promoter has been shown
to be activated in BM stromal cells (Walkley et al., 2007) that play
a pivotal role in regulating HSC function, we tested whether
PKM2 deletion affected hematopoiesis in a cell-intrinsic manner.
BM MNCs from Pkm2fl/fl:Mx1-cre+ (before deletion) or Pkm2fl/fl:
Mx1-cre mice were transplanted together with competitor BM
MNCs at a 1:1 ratio into lethally irradiated animals. After
10 weeks, the recipient mice received poly(I:C), and the periph-
eral blood was analyzed for 20 weeks. The chimerism of blood
cells was equal between the Pkm2fl/fl:Mx1-cre+ and Pkm2fl/fl:
Mx1-cre groups before poly(I:C) injection. Twenty weeks
following poly(I:C) injection, mice transplanted with Pkm2fl/fl:
Mx1-cre+ cells displayed markedly reduced chimerism in multi-
ple lineages compared with controls (Figure 2E). To further
assess the role of PKM2 in cell proliferation, we analyzed the
cell cycle status of BM cells from primary recipients by staining
with Ki-67 and DAPI. Among BM subsets, only LKS cells from
Pkm2/ mice displayed a decreased proportion in S/G2/M
phase with increased G0 phase (Figure 2F). The cycling status
of HSCs and mature cell populations was not changed (data
not shown). HSPCs seeded in methylcellulose colony assays re-
vealed no difference in colony number, but there was a slight but
statistically significant decrease in cell number (Figure 2G), sug-
gesting impaired proliferation in the absence of PKM2. These
data demonstrate that PKM2 deletion impairs the BM repopulat-
ing capacity cell-autonomously, likely by affecting progenitor cell
proliferation.ell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc. 1311
Figure 2. Deletion of PKM2 Affects the Long-Term Reconstitution Potential of HSCs
(A) BM MNCs from Pkm2fl/fl and Pkm2/ mice (CD45.1+) were mixed with competitor BM cells (CD45.2+) at a 1:1 ratio and transplanted into lethally irradiated
hosts (CD45.2+). Chimerism of multiple-lineage mature cells, including myeloid (Gr1+CD11b+), B cells (CD19+), and T cells (CD3ε+) cells, was analyzed at the
indicated time points (*p < 0.05, n = 9).
(B) BM chimerism of recipient mice from (A) was analyzed 24 weeks point posttransplantation (*p < 0.05, n = 9).
(C) HSPCs were sorted from the primary recipient mice and transplanted, with competitor BM cells, into lethally irradiated hosts. Peripheral blood (PB) was
analyzed for mature cell chimerism (*p < 0.05, **p < 0.01, n = 9-10).
(D) HSPCswere sorted from secondary recipientmice, transplanted, with competitor BMcells, into lethally irradiated hosts, and blood chimerismwas analyzed at
week 4 (*p < 0.05, n = 6).
(E) BMNMCs fromPkm2fl/fl:Mx1-cre+ orPkm2fl/fl:Mx1-cremice (no poly(I:C) treatment) were transplantedwith competitor BMat a 1:1 ratio into lethally irradiated
hosts. After 10 weeks, the recipient mice received three doses of poly(I:C), and peripheral blood chimerism was analyzed after 20 weeks. The left panel shows the
total white blood cell chimerism on the day prior to poly(I:C) treatment, and the right panel shows chimerism 20weeks after poly(I:C) injection (*p < 0.05, **p < 0.01,
***p < 0.001, n = 6–9).
(F) Cell cycle status of HSPCs from the primary BM transplantation recipient mice (*p < 0.05, **p < 0.01, n = 4-5).
(G) Proliferation assay of HSPCs. Equal numbers of LKS cells from Pkm2fl/fl and Pkm2/mice were cultured in methylcellulosemedium for 7 days under hypoxic
conditions, and the number of cells was counted (*p < 0.05, n = 3).
For all bar graphs, data represent the mean ± SEM.Metabolic Changes Induced by PKM2 Ablation and
PKM1 Expression
Given that PKM2 is important in maintaining AG in cancer cells,
we hypothesized that loss of PKM2 would lead to a more oxida-1312 Cell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc.tive metabolism in hematopoietic cells. We therefore measured
intracellular pimonidazole (Pimo) labeling of BM cells isolated
from Pimo-treated mice. Pimo reacts with free sulfhydryl groups,
such as reduced cysteine residues on proteins, to form adducts
Figure 3. Metabolic Characterization of PKM2-Deleted HSPCs
(A) Pimo staining to assess the redox state in HSPCs. Pimo was injected into Pkm2fl/fl and Pkm2/ mice. Ninety minutes later, BM cells were harvested and
stained with surface markers, followed by intracellular staining with anti-Pimo antibody. Samples were then analyzed by FACS. (**p < 0.01, ***p < 0.001, n = 5).
(B) Mitochondrial membrane potential measurement with TMRE staining, followed by flow cytometry analysis (**p < 0.01, ***p < 0.001, n = 5-6).
(C) Measurement of lactate production. LKS and LK cells were incubated in serum-free medium under normoxia (20% O2) or hypoxia (1% O2) conditions. The
concentration of lactate in the supernatant was measured 12 hr later (**p < 0.01, ***p < 0.001, n = 3).
(D) Oxygen consumption assay. Lin cells were isolated, and the OCR was measured by a Seahorse XF24 analyzer.
(E and F) HSPCs were incubated in serum-free medium for 12 hr. Cellular metabolites were extracted with 80% ice-cold methanol and analyzed by LC-MS. The
relative abundance of central metabolites (E) and amino acids (F) is shown.
For all bar graphs, data represent the mean ± SEM.that can then be detected by antibody staining (Varia et al.,
1998). At a given oxygen concentration, Pimo adduct formation
is determined by the availability of free sulfhydryl groups and,
therefore, can be used as a stable readout of the redox state
of the cell during the in vivo labeling period. In keepingwith a pre-
vious study (Takubo et al., 2010), HSCs showed higher PimoCstaining than mature cells. Depletion of PKM2 significantly
reduced the Pimo staining in both stem cell and progenitor cell
populations (Figure 3A), suggesting that these cells have a higher
oxidative state in the absence of PKM2. Next we accessedmito-
chondrial membrane potential by tetramethylrhodamine ethyl
ester (TMRE), a cell-permeant fluorescent dye that concentratesell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc. 1313
in mitochondria in proportion to the membrane potential. As
observed previously using MitoTracker (Simsek et al., 2010),
staining with TMREwas lower in HSCs than inmature cells. Inter-
estingly, Pkm2/ HSPCs, but not stem cells, displayed signifi-
cantly increased TMRE staining compared withWT counterparts
(Figure 3B), consistent with an increased mitochondrial mem-
brane potential in this population. We also observed that
PKM2 deletion led to reduced lactate production in HSPCs (Fig-
ure 3C). Interestingly, this difference was only significant when
the cells were incubated under hypoxic (1%O2) but not standard
culture conditions (20% O2) (Figure 3C). Oxygen concentrations
in the BM environment are closer to 1% than 20% (Parmar et al.,
2007; Spencer et al., 2014). Taken together, these results are
consistent with the hypothesis that loss of PKM2 and expression
of PKM1 result in a shift of glucose metabolism away from AG
at physiological oxygen concentrations. To determine whether
PKM2 depletion indeed enhanced mitochondrial respiration,
we isolated Lin cells from Pkm2fl/fl and Pkm2/ mice and
measured the oxygen consumption rate (OCR) using a Seahorse
XF analyzer. The basal respiration rate was comparable between
PKM2 WT and KO cells. However, the maximal OCR was
increased markedly in Pkm2/ cells, suggesting that the total
electron transport capacity is enhanced in the absence of
PKM2 (Figure 3D).
To further delineate the metabolic status in Pkm2/ HSPCs,
metabolites were measured. Freshly isolated LKS cells were
incubated in serum-free medium in the presence of 20% O2
overnight. Metabolites were extracted and analyzed by liquid
chromatography-mass spectrometry (LC-MS). Moderately
increased levels of tricarboxylic acid (TCA) cycle intermediates
(citrate, isocitrate, and malate) were observed (Figure 3E).
Several glycolytic intermediates upstream of PK also accumu-
lated to higher levels in Pkm2/ cells, including phosphorylated
glucose or fructose, glyceraldehyde-3-P, phosphoglycerate,
and PEP (Figure 3E). Although the PK substrate PEP accumu-
lated about 8-fold higher in PKM2/ cells than in control cells,
the amount of pyruvate was not changed. This may be explained
by an overall decrease in PK activity despite homogeneous
expression of PKM1 in PKM2 KO cells (Figure S1E) and by the
fact that pyruvate levels are affected by enzyme activities other
than PK. Elevated mitochondrial respiration in Pkm2/ cells
may reflect an increased capacity to break down pyruvate,
consistent with the lack of pyruvate accumulation. The levels
of multiple nucleotide mono- and diphosphates in Pkm2/ cells
were also altered (Figure 3E). In addition, Pkm2/ HSPCs also
displayed a moderate decrease of many amino acids, especially
nonessential amino acids that are synthesized from central car-
bon metabolic intermediates (Figure 3F). Taken together, these
data are consistent with the hypothesis that PKM2 deletion
with PKM1 expression impairs AG, enhances oxidative meta-
bolism, and limits the macromolecule biosynthesis required for
cell proliferation.
Deletion of LDHA Compromises Long-Term BM
Repopulation Capacity via a Different Mechanism Than
that Observed in Pkm2/ Mice
To further test whether AG is indeed important for hematopoiesis
and leukemogenesis, we generated a mouse strain with floxed1314 Cell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc.LDHA (Ldhafl/fl) alleles. LDHA is the predominant LDH isoform
expressed in mouse BM hematopoietic cells (Figure 4A). LDHA
conditional mice (Ldhafl/fl) (Figure S2A) were crossed to Mx1-
cre mice. Deletion of LDHA was induced by poly(I:C) and
confirmed by genomic DNA and mRNA analysis (Figure 4B; Fig-
ures S2B–S2D). LDHA deletion did not cause upregulation of
LDHB (data not shown). Lactate production by Ldha/ HSPCs
decreased dramatically compared with WT cells under both nor-
moxic and hypoxic conditions (Figure 4C), suggesting that loss
of LDHA abrogated both aerobic and anaerobic glycolysis.
Erythropoiesis was affected markedly by LDHA deletion, as
anticipated, because red cells depend upon LDH, but no acute
changes in other BM hematopoietic cells under homeostatic
conditions were observed (data not shown). Serial BM compet-
itive transplantation was then performed to test whether LDHA is
important for hematopoiesis under stress conditions. In the pri-
mary transplantation, there was an initial advantage of Ldha/
BM in repopulating multilineage blood cells, but this advantage
disappeared at a later time point (Figure 4D). When the BM
from the primary recipients was transplanted into secondary re-
cipients, Ldha/ BM displayed marked defects in repopulation
capacity (Figure 4E) with dramatically decreased chimerism
among HSCs and others in BM (Figure 4F).
Because deletion of LDHA resulted in a loss of lactate produc-
tion and defects in long-term BM repopulation, we hypothesized
that LDHA depletion impairs the growth and expansion of rapidly
proliferating progenitor cells. To test this, HSPCs were cultured
in cytokine-supplementedmethylcellulose medium under condi-
tions of normoxia (20% O2) or hypoxia (1% O2) for 1 week, and
the numbers of colonies and cells were counted. Under nor-
moxic conditions, Ldha/ HSPCs failed to form colonies (Fig-
ures 4G). When cultured under hypoxic conditions, Ldha/ cells
were able to form colonies but with a markedly smaller size
compared with the WT group (Figure S3A). The average number
of cells per colony in the Ldha/ group was decreased by over
60% (Figure 4G). Similar results were obtained when whole BM
(WBM) cells were cultured (Figures S3B and S3C). Cell cycle
analysis showed that the percentage of cycling cells (S/G2/M)
was lower in both progenitor and stem populations from Ldha/
mice (Figure 4H). Expression of Cyclin D1, a gene important for
cell cycle progression through G1 phase (Baldin et al., 1993),
was decreased markedly in Ldha/ HSPCs (Figure S3D). More-
over, decreased expression of HIF1a pathway genes (Hif1a,
Pdk1, and Slc2a1) and antiapoptotic genes (Bcl-2 and Bcl-XL)
was noted in Ldha/ HSPCs (Figure S3E).
Because loss of PKM2 moderately decreased lactate produc-
tion under hypoxia whereas LDHA deletion abrogated over 90%
of lactate generation, regardless of oxygen abundance, we hy-
pothesized that Ldha/ cells exclusively utilize mitochondrion
respiration to regenerate NAD+ to allow continued glucosemeta-
bolism. Indeed, both basal and maximal respiration rates were
elevated markedly in Ldha/ Lin cells compared with WT con-
trol cells (Figure 5A). In addition, hematopoietic progenitor and
stem cells from Ldha/ mice exhibited higher staining for
TMRE (Figure 5B) and lower staining for Pimo (Figure 5C), sug-
gesting an enhanced mitochondrial membrane potential and a
more oxidative state in these cells. Metabolite profiling also re-
vealed that depletion of LDHA led to accumulation of upstream
Figure 4. LDHA Plays Important Roles in Long-Term Hematopoiesis
(A) In-gel zymography of LDHA and LDHB in HSPC, heart (H), and muscle (M).
(B) qPCR analysis of LDHA transcripts in BMMNCs from Ldhafl/fl:Mx1-cre+ (Ldha/) and Ldhafl/fl:Mx1-cre+ (Ldhafl/fl) following poly(I:C) injection (*p < 0.05, n = 3).
(C) Lactate production by HSPCs. HSPCs were incubated in serum-free medium under normoxia (20% O2) or hypoxia (1% O2) conditions for 12 hr. The con-
centration of lactate in the supernatant was measured (***p < 0.001, n = 3).
(D) PB chimerism in primary BM transplantation (**p < 0.01, ***p < 0.001, n = 10). B, B cell; T, T cell.
(E) PB chimerism in secondary BM transplantation (*p < 0.05, **p < 0.01, ***p < 0.001, n = 7-10).
(F) BM chimerism in secondary recipients 24 weeks after posttransplantation (***p < 0.001, n = 5-9).
(G) HSPCs were plated in methylcellulose medium and incubated under normoxic (20% O2) or hypoxic (1% O2) conditions for seven days. The numbers of
colonies (left) and cells per colony (right) were counted (***p < 0.001, n = 3-4). NA, not assigned.
(H) Cell cycle analysis showing that LDHA deletion reduces the frequency of cycling cells (S/G2/M) in both LKS and SLAM populations (*p < 0.05, **p < 0.01,
***p < 0.001, n = 5-6).
For all bar graphs, data represent the mean ± SEM. See also Figure S3.
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Figure 5. Antioxidant Treatment Partially Rescues the Functional Defects of Ldha/ BM Cells In Vitro and In Vivo
(A) Lin cells were isolated from Ldhafl/fl and Ldha/ mice, and the OCR was measured by a Seahorse XF24 analyzer.
(B) Mitochondrial membrane potential measurement with TMRE staining, followed by flow cytometry analysis (***p < 0.001, n = 6-7).
(C) Pimo staining showing a higher oxidative state in Ldha/ HSPCs and HSCs (*p < 0.05, **p < 0.01, ***p < 0.001, n = 5).
(legend continued on next page)
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glycolytic intermediates (Figure S4A). Interestingly, the abun-
dance of TCA cycle intermediates was not changed, despite
an increased OCR. The levels of multiple nucleotide monophos-
phates and diphosphates and amino acids were also decreased
in LDHA-deleted cells compared with controls (Figures S4A and
S4B), consistent with reduced anabolic activity upon LDHA
depletion. In addition to supporting energy production, electron
transfer along the mitochondrial respiration chain contributes to
the formation of ROS. To test whether enhanced oxygen con-
sumption resulted in higher ROS production, we analyzed BM
cells using a ROS indicator, carboxy-H2DCFDA. Although
PKM2 deletion did not change the ROS level (data not shown),
all BM subsets, including HSCs from Ldha/ mice, exhibited
enhanced levels of ROS (Figure 5D). Because excess ROS has
been shown to impair HSC maintenance and long-term repopu-
lation ability (Ito et al., 2004), the increased production of ROS in
Ldha/mice, but not Pkm2/mice, may explain why the stem
cell pool was compromised in the former but maintained in the
latter throughout serial transplantation.
Testing whether excess ROS contributes to functional defects
of Ldha/ HSPCs, we performed a rescue experiment by using
the antioxidant N-acetyl-L-cysteine (NAC). NAC has been re-
ported to decrease ROS both in vitro and in vivo (Ito et al.,
2004; Miyamoto et al., 2007). First, HSPCs were cultured with
or without NAC for 48 hr. Although NAC did not alter the levels
of ROS in HSPCs from Ldhafl/fl mice, it decreased ROS levels
in Ldha/ HSPCs (Figure 5E) and partially rescued the in vitro
growth defect of Ldha/ HSPCs (Figure 5F). To determine
whether NAC was able to reverse the increased ROS levels
in vivo, Ldha/ or control mice were fed regular water or water
containing NAC immediately after the last dose of poly(I:C) for
8 weeks. The elevated ROS level in Ldha/ mice was reversed
completely by NAC (Figure 5G). Finally, we testedwhether in vivo
NAC treatment also rescued the long-term repopulating defect
of LDHA KO BM. Serial BM transplantation was performed,
and regular or NAC-containing water was provided throughout
the experiment (16 weeks for primary animals and 20 weeks
for secondary animals). Analysis of white blood cell chimerism
in secondary recipient animals revealed partial rescue of
Ldha/ BM function by NAC treatment (Figure 5H). The func-
tional rescue of Ldha/ cells by NAC appears to be at the level
of stem cells because the long-term HSCs in the BM were
partially recovered by NAC (Figure 5I).
These data demonstrate that loss of LDHA suppresses the
proliferation of progenitors and compromises long-term stem(D) Intracellular ROS levels were increased upon LDHA deletion (*p < 0.05, **p <
(E) In vitro NAC treatment reverses increased ROS in Ldha/ HSPCs. Freshly iso
NAC (NAC) for 48 hr. Cells were then stained with carboxy-H2DCFDA, followe
(F) In vitro NAC treatment reverses the defects in daughter production of Ldha/H
without NAC for 1 week, and cell numbers were counted (***p < 0.001, n = 3). NS
(G) In vivo NAC treatment reverses increased ROS levels in LDHA/ HSPCs. Im
divided into two groups. One group was fed regular water, and the other group
sessed by staining with carboxy-H2DCFDA, followed by flow cytometry analysis
(H and I) In vivo NAC treatment partially rescues the long-term repopulation defe
performed as described in Figure 4. In both primary and secondary transplantat
40 mM NAC (+NAC) immediately following bone marrow transplant (BMT). The du
the blood (H) and BM (I) of the secondary recipients was analyzed 20 weeks afte
For all bar graphs, data represent the mean ± SEM.
Ccells. The effect on stem cells is caused, at least partially, by
increased ROS upon LDHA depletion. Therefore, metabolic
changes of different magnitudes resulting from deletion of the
two glycolytic genes, PKM2 and LDHA, both impair the long-
term repopulation capacity but appear to affect different he-
matopoietic cell populations.
Impact of Altered Glycolysis on Leukemogenesis In Vivo
Although some studies suggest that PKM2 can play a role in can-
cer cell proliferation (Chaneton et al., 2012; Christofk et al.,
2008a; Goldberg and Sharp, 2012; Luo et al., 2011; Lv et al.,
2011), other studies show that this isoform is not required for tu-
mormaintenance and growth (Corte´s-Cros et al., 2013; Israelsen
et al., 2013). Inhibition of LDHA leads to oxidative stress and anti-
tumor effects in cancer cell lines (Fantin et al., 2006;Granchi et al.,
2011; Le et al., 2010). Those reports, however, are mainly based
onstudiesof cell linesderived fromsolid tumors. Leukemiagrows
in a very different tissue environment. To address whether in vivo
leukemogenesis relies on AG, we transduced the human leuke-
mia gene BCR-ABL or MLL-AF9 into mouse BM cells to induce
chronic myeloid leukemia (CML)-like or acute myeloid leuke-
mia (AML)-like disease, respectively. These leukemic alleles are
thought to induce disease in different subpopulations of hemato-
poietic cells. BCR-ABL induces a stemcell-based disease (Taka-
hashi et al., 1998), and MLL-AF9 induces a myeloid progenitor
(GMP) disease (Krivtsov et al., 2006). These models, therefore,
could test whether the differential effect of LDHA and PKM2 on
normal stem and progenitor cells might result in distinct effects
on leukemogenesis. PKM2 or LDHA KO and control mice were
given 5-flurouracil (5-FU) (150 mg/kg), and BM cells were har-
vested 5 or 6 days later and infected with a retrovirus expressing
BCR-ABLorMLL-AF9.Next, equal numbersof infectedWTorKO
cells were injected together with equal numbers of supporting
normal BM cells into lethally irradiated mice for leukemia
development. For both CML and AML, mice transplanted with
Pkm2/ or Ldha/ cells displayed significantly prolonged
disease latency (Figures 6A and 6B). Expression of Cyclin D1
was markedly lower in Pkm2/ and Ldha/ leukemic cells
compared with WT control cells (Figure 6C). As in normal BM,
PKM1 was expressed in PKM2/ leukemic cells, and the dele-
tion of PKM2 and LDHA was maintained through disease pro-
gression in mice initially transplanted with Pkm2/ and Ldha/
cells, respectively (Figures S5A–S5D).
We next sought to determine whether the leukemogenesis
defect observed from PKM2 and LDHA knockout cells was0.01, n = 5).
lated HSPCs were incubated in medium supplemented with (+NAC) or without
d by flow cytometry analysis (***p < 0.001, n = 3).
SPCs. Two thousand HSPCs were cultured in methylcellulose mediumwith or
, not significant.
mediately following poly(I:C) injection, LDHA-deficient and control mice were
was fed water containing 40 mM NAC for 8 weeks. Intracellular ROS were as-
(***p < 0.001, n = 4-6).
cts of Ldha/ BM in a serial transplantation assay. Serial transplantation was
ions, recipient mice were fed either regular water (NAC) or water containing
ration of primary BMT was 16 weeks. The chimerism of hematopoietic cells in
r transplantation (*p < 0.05, n = 5).
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accompanied by alterations in cellular metabolism. Deletion of
PKM2 or LDHA resulted in decreased AG in leukemic cells, as re-
vealed by decreased lactate production (Figures 6D and 6E).
Interestingly, the extent to which glycolysis is inhibited is mark-
edly different between these two mutants. Whereas Pkm2/
leukemic cells produced approximately 30% less lactate than
WT cells under hypoxic conditions (Figure 6D), loss of LDHA
suppressed >90%, regardless of oxygen tension (Figure 6E),
and markedly reduced glucose consumption (Figure S5E). In
contrast to reduced lactate production, oxygen consumption
was increased in both Pkm2/ and Ldha/ leukemic cells
compared with WT control cells (Figure 6F), suggesting
enhanced mitochondrial respiration in the absence of PKM2 or
LDHA. Measurement of intracellular metabolites revealed a pro-
file similar to that seen in corresponding HSPCs. Both Pkm2/
and Ldha/ leukemic cells have higher levels of glycolytic inter-
mediates and lower levels of multiple amino acids compared
with control cells (Figure S6). Pkm2/ leukemic cells also have
a higher abundance of TCA cycle intermediates (Figure S6).
These data suggest that depletion of PKM2 or LDHA enforces
a metabolic shift from glycolysis to mitochondrial respiration
and compromises leukemia induction in mice.
Recently PKM2 has been reported to play a critical role in pro-
tecting acute oxidative stress in human lung cancer cells (Anas-
tasiou et al., 2011). Given that depletion of PKM2 or LDHA in
leukemic cells enhanced mitochondrial respiration, we asked
whether these cells have a compromised capacity for ROS
buffering. AML cells from leukemic mice were incubated in the
presence or absence of paraquat, a potent generator of mito-
chondrial ROS, for up to 8 hr. Intracellular ROS was measured
by MitoSox Red staining. Endogenous ROS levels without para-
quat treatment were comparable between Pkm2/, Ldha/,
and WT leukemic cells (Figure S7A). Treatment with paraquat
drastically enhanced intracellular ROS in all groupswith equal ef-
ficiency. By staining with viability dye, we also observed a higher
death rate in Ldha/ leukemic cells (Figure S7B). Although
elevating intracellular ROS, paraquat did not further induce
cell death in Pkm2/ or Ldha/ leukemic cells. Therefore, we
conclude that depletion of PKM2 or LDHA does not impair the
ROS buffering capacity in AML cells.
Given that PKM2 and LDHA are important for leukemia initia-
tion, we asked whether they are also important for leukemia
maintenance and whether a differential sensitivity exists be-
tween normal and malignant cells in response to targeting these
two enzymes. Therefore, BM MNCs were prepared from 5-FU-
treated Pkm2fl/fl:Mx1-cre+ or Ldhafl/fl:Mx1-cre+ mice and in-
fected with the MLL-AF9 retrovirus. Virally transduced cellsFigure 6. Loss of Either PKM2 or LDHA Extends Disease Latency of M
(A) Pkm2fl/fl:Mx1-cre+ and Pkm2fl/fl:Mx1-cre mice were treated with poly(I:C). A
mononuclear cells were harvested, infected with a retrovirus expressing BCR-ABL
mice for disease development. A Kaplan-Meier survival curve for animals that de
(B) Kaplan-Meier survival analysis of animals transplanted with retrovirally transd
(C) qPCR analysis of Cyclin D1 (Ccnd1) mRNA expression in leukemic cells (**p
(D) Lactate production by Pkm2fl/fl and Pkm2/ CML cells (***p < 0.001, n = 5).
(E) Lactate production by Ldhafl/fl and Ldha/ AML cells (***p < 0.001, n = 3). D
(F) Measurement of the oxygen consumption rate of AML leukemic cells.
Also see Figures S5, S6, and S7.
Cwere transplanted, and, after leukemia developed, GFP+
leukemic cells (Pkm2fl/fl:Mx1-cre+ or Ldhafl/fl:Mx1-cre+) were iso-
lated and cotransplanted with normal BM MNCs that bear the
same floxed gene and the Mx1-cre gene into lethally irradiated
mice. Two weeks later, the secondary recipients were given
PBS or poly(I:C) to delete PKM2 or LDHA (Figure 7A). Poly(I:C)
does not change leukemia growth on a WT background (Sykes
et al., 2011). Mice were assessed for leukemic burden by spleen
weight and leukemic cell (GFP+) counts in the peripheral blood
and BM. In parallel, the numbers of nonleukemic GFP cells
were also quantified to evaluate the effect of PKM2 or LDHA
deletion on normal hematopoiesis within the same time window.
Deletion of either PKM2 or LDHA significantly suppressed leuke-
mia progression (Figures 7B–7D), whereas normal white blood
cells were not decreased by depletion of either gene (Figures
7C and 7D). Indeed, normal cells were actually increased
following deletion of either PKM2 or LDHA. These data suggest
that the glycolytic pathway is important for leukemia mainte-
nance and progression and that leukemic cells are more sensi-
tive to the inhibition of AG than normal hematopoietic cells.
DISCUSSION
Matching metabolic output with the demands of cellular function
is essential for tissue integrity under homeostatic and stress con-
ditions. This study demonstrates that PKM2 deletion appears to
enhance oxidative phosphorylation at the expense of glycolysis
and biomass intermediates in primary hematopoietic progeni-
tors. These results are consistent with a model in which this
highly proliferative compartment depends upon AG. The lack
of change in ROS upon PKM2 depletion suggests that the de-
gree to which oxidative glucose metabolism is used is neither
as dramatic as LDHA deletion nor sufficient to affect HSC func-
tion. The fact that the metabolic parameters are perturbed does
not exclude a role for nonmetabolic PKM2 functions, as has been
proposed by others (Luo et al., 2011; Lv et al., 2011; Yang et al.,
2011). However, deletion of another metabolic regulator of
glycolysis, LDHA, also induced a progenitor defect, thereby sug-
gesting that it is the metabolic functions of PKM2 that dominate
in the progenitor phenotype.
In the case of LDHA depletion, there is a loss of HSCs as
well as a compromise in progenitor function. The compromise
of HSC number is in association with a greater compromise of
AG in the LDHA mutant animal and sufficient activation of mito-
chondrial respiration to generate a detectable increase in ROS.
Because the functional defect of LDHA deletion can be partially
rescued by antioxidants, it is likely that the excessive ROS levelsyeloid Leukemia in Mice
fter 4 weeks, these animals were given 5-FU (150 mg/kg). Six days later, BM
(CML) or MLL-AF9 (AML), and transplanted into sublethally irradiated recipient
veloped leukemia is shown.
uced BM cells prepared from Ldhafl/fl and Ldha/ mice.
< 0.01,***p < 0.001, n = 3). Data represent the mean ± SEM.
Data represent the mean ± SEM.
ata represent the mean ± SEM.
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Figure 7. Deletion of PKM2 or LDHA Retards Progression of Established Leukemia without Compromising Normal Hematopoietic Cells
(A) Experimental scheme. BM MNCs from 5-FU-treated Pkm2fl/fl:Mx1-cre+ or Ldhafl/fl:Mx1-cre+ mice were infected with MLL-AF9 virus to generate primary
leukemia. Fifty thousand primary leukemic cells (GFP+) were cotransplanted with 500,000 normal BM cells (GFP) that contained the same floxed gene and
Mx1-cre into lethally irradiated hosts. Seven to ten days later, the recipient mice were administered saline (Pkm2fl/fl, Ldhafl/fl) or poly(I:C) to delete the Pkm2 or
Ldha gene (Pkm2/, Ldha/). At the first presentation of leukemia, all mice were euthanized to assess the leukemia burden.
(B) Size and mean weight of spleens (n = 6). Data represent the mean ± SEM.
(C) The numbers of leukemic cell (GFP+) and normal hematopoietic cells (GFP) in peripheral blood.
(D) The numbers of leukemic cell (GFP+) and normal hematopoietic cells (GFP) in the BM.
Data represent the mean ± SEM (*p < 0.05, ***p < 0.001, n = 6).lead to a decrease in HSC maintenance (Ito et al., 2004). The
phenotype of the LDHA mutant resembles that of the PDK
mutant (Takubo et al., 2013) in that both display defects in
long-term repopulating activity following transplantation. How-
ever, inhibition of PDK only affects stem cells, whereas deletion
of LDHA compromises both stem and progenitor populations.
Such a distinction may be explained by a differential magnitude
in the shift away from AG. PDK indirectly inhibits the conversion
of pyruvate to acetyl-coenzyme A to decrease pyruvate oxida-
tion, whereas LDHA is a direct mediator of pyruvate fermentation
to lactate.
Notably, neither modest (Pkm2/) nor extreme (Ldha/)
inhibition of AG was sufficient to prevent the development of
leukemia induced by the two leukemogenic alleles studied.
These data indicate that this metabolic program is not an
absolute requirement for cancer initiation. Establishment of
malignancy is not dependent on either the metabolic or other
putative roles of PKM2, but the progression of either a stem
cell-driven (BCR-ABL) or progenitor cell-driven (MLL-AF9) leu-1320 Cell 158, 1309–1323, September 11, 2014 ª2014 Elsevier Inc.kemia was compromised when the glycolytic enzymes were
deleted.
A different phenotype was observed when PKM2 was
deleted in a mouse model of breast cancer (Israelsen et al.,
2013) with accelerated disease and PKM1 re-expression in
the nonproliferating subpopulation of tumor cells. Those data
indicate that PKM2 deletion and no re-expression of PKM1
are associated with tumor proliferation, whereas PKM1 may
be required by nonproliferating cells to survive environmental
stress in a solid tumor. It remains to be determined whether
PKM1 expression increases total PK activity in nonproliferating
tumor cells and whether the differential expression pattern of
PKM1 leads to additional metabolic alterations. In the hemato-
poietic system, PKM1 expression was observed in all cells
following PKM2 deletion. Hematopoietic progenitor cell func-
tion is not affected by PKM2 deletion under homeostatic condi-
tions but is compromised during the stress of transplantation
that drives rapid cell proliferation. This suggests that replacing
PKM2 with PKM1 results in a loss of flexibility to tune PK
activity that is critical for cells to meet different metabolic
needs. Fast-growing cells such as hematopoietic progenitor
or leukemic cells rely on the capability of PKM2 to regulate their
PK activity to support anabolic metabolism. Therefore, the dif-
ference in disease outcome between these two models may be
explained by the differential expression pattern of PKM1. This
may also reflect a distinct metabolic dependency between
these two tissue types.
Leukemia of either of the two types studied appears to use
metabolic processes important for normal hematopoiesis to its
advantage and, by doing so, may acquire a disproportionate
vulnerability to disruption of those pathways. Although the
impairment of glycolysis induced by either PKM2 or LDHA dele-
tion affected normal hematopoietic function only under the
stress condition of serial transplantation, its effects on leukemic
latency were evident with the first transplantation. In addition,
parallel depletion of either of these two genes in normal and ma-
lignant cells markedly compromises leukemic cell growth but not
normal hematopoiesis. These observations imply a therapeutic
window where suppression of glycolysis may preferentially
reduce the kinetics of leukemia cell growth. However, the
LDHA data indicate that extreme suppression of glycolysis
may have more marked effects on normal hematopoiesis. These
data, therefore, suggest that leukemia, like the normal cells from
which it arises, depends upon how glucose is metabolized, and
therapeutic shifts away from AG must be titrated carefully to
avoid compromise of the regenerative processes on which tis-
sue maintenance depends.
EXPERIMENTAL PROCEDURES
Mice
Generation of the Pkm2fl/+ mouse strain has been described previously (Isra-
elsen et al., 2013). Pkm2fl/+:Mx1-cre+ and Pkm2fl/+:Mx1-cre mice were
crossed to obtain Pkm2fl/fl:Mx1-cre+ and Pkm2fl/fl:Mx1-cre mice. The
Ldhafl/+ mouse was generated by crossing Ldhatm1a(EUCOMM)Wtsi to the FLP
transgenic mouse and then to Mx1-cre+ to create Ldhafl/fl:Mx1-cre mice.
Deletion of PKM2 or LDHA was achieved by i.p. injection of poly(I:C) every
other day for 6 days. All mice were maintained under pathogen-free condi-
tions according to the guidelines of the Institutional Animal Care and Use
Committee.
Flow Cytometry and Antibodies
BM MNCs were stained with a cocktail of biotinylated antibodies for CD3ε,
CD4, CD8, CD11b, CD45R/B220, Gr-1, Ter119, and IL-7R and then with fluo-
rochrome-tagged streptavidin and antibodies for stem/progenitor cell
markers, including cKit, Sca1, CD48, and CD150. When necessary, the sam-
ples were then fixed and permeabilized for intracellular staining with PKM1 and
PKM2 antibodies. The samples were analyzed with an LSRII flow cytometer
(Beckman Decon). To isolate HSPCs, BM MNCs were stained with lineage
cocktail antibodies followed by incubation with streptavidin-loaded magnetic
beads. The suspension was passed through a magnate column to remove all
lineage-positive cells. Lin cells were then stainedwith antibodies against cKit,
Sca1, CD150, and CD48 and subjected to sorting using a FACSAria instrument
(Beckman Decon).
Bone Marrow Transplantation
For whole BM transplantation, 5 3 105 BM MNCs from the indicated mice
were cotransplanted with an equal number of WT cells into lethally irradiated
congenic mice. For HSPC transplantation, 2,000 LKS cells were transplanted
with 43 105 competing BM into lethally irradiated recipient animals. To induce
leukemia in mice, BM MNCs were harvested from 5-FU-treated mice andCinfected with murine stem cell virus (MSCV) containing MLL-AF9 or BCR-
ABL and GFP genes. Equal numbers of infected cells were cotransplanted
with supporting BM MNCs into lethally irradiated mice for leukemia
development.
Measurement of ROS, Mitochondrial Membrane Potential, and
Cellular Hypoxia
Cellular ROS were measured by staining cells with 5-(and -6)-carboxy-20,70-
dichlorodihydrofluorescein diacetate (carboxy-H2DCFDA) or MitoSox Red
(Life Technologies), followed by flow cytometry analysis. The mitochondrial
membrane potential was analyzed with flow cytometry for TMRE staining
(Life Technologies). To measure the cellular redox status, mice were injected
with 60 mg/kg Pimo. Ninety minutes later, BM cells were harvested and
stained with surfacemarkers, followed by intracellular staining with fluorescein
isothiocyanate (FITC) anti-Pimo antibody (Hyproxyprobe). Fluorescence-acti-
vated cell sorting (FACS) analysis was performed with an LSRII flow cytometer
(Beckman Decon).
Oxygen Consumption Assay
TheOCRwas analyzed in an XF24 extracellular flux analyzer (Seahorse Biosci-
ences) as described previously (Wu et al., 2007) and following the manufac-
turer’s protocol. Additional details are described in the Extended Experimental
Procedures.
Measurement of Metabolites
HSPCs or leukemic cells were incubated in StemSpan serum-free medium
(STEMCELL Technologies) for 8–10 hr. Cells were lysed in ice-cold 80%meth-
anol containing 0.1% formic acid, dried, and reconstituted in water. The solu-
ble faction was analyzed by LC-MS as described previously (Christofk et al.,
2008a). Lactate and glucose in the supernatant were measured by a YSI
7100 bioanalytical system (YSI Life Sciences).
Statistical Analyses
Unpaired, two-tailed Student’s t tests were used for analyses comparing two
experimental groups. Log rank tests were used on Kaplan-Meier survival ana-
lyses. For all bar graphs, data are represented as mean ± SEM.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
seven figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cell.2014.07.048.
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